Back to School: How biopharma can reboot drug development. Access exclusive analysis here

King petitions against ZymoGenetics' rThrombin

KG said it submitted a Citizen's Petition to FDA asserting that ZGEN has not provided the agency with adequate data

Read the full 209 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE